Lode-Star Mining acquires patented EGCG molecule assets from Sapir Pharmaceuticals for $1M in preferred stock

FinTrade Sherpa, Inc.

Acquired all assets related to stabilized EGCG molecule for pharmaceutical development.
Consideration: 1,000,000 Series A Convertible Preferred shares valued at $1.00 each, convertible to common at 450:1.
Sapir receives 5% royalty on gross revenues from licensed or derived products; paid quarterly for 5 years, extendable.
Sapir gets 450 votes per preferred share; restrictions on reverse splits and new preferred issuance for one year.
Transaction closed Dec 28, 2021; press release issued Dec 30, 2021.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.